378,550 Shares in BioLife Solutions, Inc. $BLFS Purchased by Capricorn Fund Managers Ltd
Capricorn Fund Managers Ltd recently acquired a significant stake of 378,550 shares in BioLife Solutions (NASDAQ:BLFS), valued at approximately $9.15 million, making BLFS its 12th largest position. Despite insider sales totaling over $2 million in the last three months, institutional investors own 93.24% of the stock. Analysts currently hold a "Moderate Buy" consensus rating with a target price of $32.00 for BioLife Solutions, which specializes in biopreservation and cold chain solutions for advanced biologics.
BLFS Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial analysis of BioLife Solutions Inc (BLFS), detailing its revenue breakdown, profitability margins, and a comparison with competitors. The company primarily generates revenue from Product Revenue-Cell processing, showing strong gross margins but a negative Return on Equity. It also benchmarks BLFS's financial performance against industry leaders like STAA and CDNA.
BioLife Solutions (BLFS) executive sells 2,577 shares under 10b5-1 plan
Karen A. Foster, Chief Quality and Operations at BioLife Solutions (BLFS), sold 2,577 shares of common stock at a weighted average price of $19.17 per share. This transaction was conducted under a pre-arranged Rule 10b5-1(c) trading plan adopted in December 2025. Following the sale, Foster directly holds 108,758 shares of BioLife Solutions common stock.
Global Biostorage Service Market Size is Expected to Reach USD 655.81 Million by 2026
The global Biostorage Service market is projected to reach $1,658.22 million by 2033, growing from $655.81 million in 2026 with a CAGR of 14.17%. This growth is driven by advancements in precision medicine, biopharmaceutical R&D, and the expansion of new drug development. Key market players include Azenta, Thermo Fisher Scientific, and EPL Archives (VWR), with North America being the largest market.
Foster Karen A., chief quality and operations, sells BioLife Solutions (BLFS) shares for $49k
Karen A. Foster, Chief Quality and Operations at BioLife Solutions Inc (NASDAQ:BLFS), recently sold 2,577 shares for a total of $49,401 under a Rule 10b5-1 trading plan. This insider sale occurred as BLFS trades just 7% above its 52-week low and is down 22% year-to-date. Despite the insider sale, the company reported strong financial performance in Q4 2025, exceeding analysts' expectations for both EPS and revenue.
BioLife Solutions Inc (BLFS) Stock Price Quote Today & Current Price Chart
This entry appears to be a stub or an incomplete article. It mentions BioLife Solutions Inc (BLFS) stock price quotes and current price charts, suggesting it is a financial data page. The only content provided points to "Online Trading with Smart Investment App" from Capital.com.
Vanguard (BLFS) Amendment shows 0 shares and 0% after Jan 12, 2026 realignment
Vanguard Group filed an amended Schedule 13G/A for BioLife Solutions Inc. (BLFS), reporting 0 shares and 0% beneficial ownership an internal realignment on January 12, 2026, which led to disaggregated reporting by its subsidiaries. This change is purely an accounting and disclosure adjustment, not an actual sale of shares by Vanguard, and reflects a switch to separate reporting by its various units based on SEC guidance. The filing clarifies that Vanguard Group no longer has beneficial ownership of BLFS shares held by these subsidiaries but does not indicate any change in aggregate shareholder ownership levels or transaction activity.
BLFS SEC Filings - Biolife Solutions Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Biolife Solutions Inc. (BLFS) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event reports (8-K), and insider trading forms. It offers detailed information on the company's activities in cell processing tools, bioproduction products, and financial reporting. The platform also provides AI-powered summaries of these filings to help investors understand key points and corporate governance decisions.
BioLife Solutions (BLFS) CMO uses shares to cover tax bill
BioLife Solutions Inc. (BLFS) Chief Marketing Officer Todd Berard reported an insider tax-withholding transaction where 1,879 shares of common stock were withheld to cover his tax obligations upon the release of restricted stock units. This non-market disposition leaves Berard with 164,061 directly held shares of BioLife Solutions common stock. This is a routine transaction for equity compensation tax liabilities.
BioLife Solutions (BLFS) CEO uses 11,101 shares for tax withholding
Roderick De Greef, President and CEO of BioLife Solutions Inc. (BLFS), had 11,101 shares of common stock withheld to cover taxes on vested restricted stock units. This transaction was a tax-withholding disposition, meaning the shares were delivered back to the company rather than sold on the open market. Following this, De Greef directly holds 733,746 shares of BioLife Solutions common stock.
BioLife Solutions (BLFS) CFO has shares withheld to cover RSU taxes
BioLife Solutions Inc.'s CFO, Troy Wichterman, had 3,749 shares of common stock withheld at $19.12 per share to cover tax obligations related to the vesting of restricted stock units (RSUs). This was a routine, non-market transaction to satisfy taxes, not a sale, and Wichterman retains a significant equity position of 216,900 shares after the transaction. This type of insider transaction is generally considered a neutral signal as it's an administrative event for equity compensation.
BioLife Solutions, Inc. (NASDAQ:BLFS) Given Consensus Recommendation of "Moderate Buy" by Brokerages
BioLife Solutions, Inc. (NASDAQ:BLFS) has received a consensus "Moderate Buy" rating from five brokerages, with an average one-year price target of $32.00. Despite a negative P/E ratio indicating unprofitability, the company, which specializes in biopreservation solutions for cell and gene therapies, has seen significant institutional investment and some insider selling. The stock is currently trading at $19.12, below its 1-year high of $29.62.
BioLife Solutions, Inc. $BLFS Shares Sold by Granahan Investment Management LLC
Granahan Investment Management LLC significantly reduced its stake in BioLife Solutions (NASDAQ:BLFS) by 39% in the third quarter, selling 251,104 shares. This transaction leaves them with 392,096 shares, valued at approximately $10 million. Additionally, insiders have been selling shares, with Karen A. Foster disposing of 96,923 shares and a total of 101,956 insider shares sold in the last three months.
BioLife Solutions, Inc. $BLFS Shares Sold by Fred Alger Management LLC
Fred Alger Management LLC reduced its stake in BioLife Solutions (NASDAQ:BLFS) by 11.1% in Q3, selling 139,106 shares and retaining over 1.1 million shares valued at approximately $28.3 million. Company insiders also sold about 101,956 shares worth $2.07 million last quarter, with Karen A. Foster being a significant seller. Analysts currently hold a "Moderate Buy" rating for BLFS with a consensus target price of $32.00, despite the stock trading below its 50- and 200-day moving averages.
BioLife Solutions, Inc. (BLFS) surpasses Q4 earnings and revenue estimates
BioLife Solutions, Inc. (BLFS) announced strong fourth-quarter results, surpassing both earnings and revenue estimates. The company reported adjusted earnings of $0.09 per share, significantly outperforming the Zacks Consensus Estimate of a $0.05 loss, and revenues of $37.2 million, exceeding the estimate of $35.45 million. This positive performance was largely driven by robust growth in its cell processing and storage and distribution segments.
BioLife Solutions, Inc. (BLFS) surpasses Q4 earnings and revenue estimates
BioLife Solutions, Inc. (BLFS) exceeded Q4 earnings and revenue expectations. This performance indicates a stronger financial footing than anticipated by analysts. Further details within the full report would likely elaborate on the factors contributing to this positive outcome.
BioLife Solutions, Inc. $BLFS is Casdin Capital LLC's 2nd Largest Position
Casdin Capital LLC has made BioLife Solutions (BLFS) its second-largest holding, despite reducing its stake by 13% in Q3. The article highlights significant insider selling, with two executives selling shares totaling over $2 million. Wall Street analysts currently rate BLFS as a "Moderate Buy" with an average price target of $32.00, while the stock trades between $18–$25.
BLFS - Biolife Solutions Inc Latest Stock News & Market Updates
This page provides news and analysis for Biolife Solutions (BLFS), a developer of cell processing tools and services for the cell and gene therapy markets. It covers financial results, strategic transactions, product developments, and corporate updates. Recent news includes details on preliminary Q2 2020 revenue, a public stock offering, and second-quarter financial results.
BioLife Solutions (NASDAQ: BLFS) officer sells 97K shares in open market
Karen A. Foster, BioLife Solutions' Chief Quality and Operations officer, sold a total of 97,423 shares of common stock in open-market transactions. The sales occurred at weighted average prices of $20.15 and $20.00 per share. Following these transactions, Ms. Foster directly owns 113,242 shares of BioLife Solutions common stock.
BioLife Solutions (NASDAQ:BLFS) Hits New 1-Year Low on Insider Selling
BioLife Solutions (NASDAQ:BLFS) recently hit a new 52-week low after an insider, Karen A. Foster, sold 96,923 shares for approximately $1.95 million, reducing her stake by 46%. Despite this insider selling and the stock trading below its moving averages, analysts maintain a "Moderate Buy" consensus rating with an average target price of $32.00. The company, which specializes in biopreservation and cold chain solutions, has a market capitalization of $929.87 million and is largely held by institutional investors.
BioLife Solutions Officer Sells Shares
Karen A. Foster, Chief Quality and Operations Officer at BioLife Solutions (BLFS), sold 97,423 shares of common stock in transactions on March 5 and March 9, 2026, totaling $1,962,998. The weighted average selling prices were $20.15 and $20.00 per share. Following these sales, Foster retains direct ownership of 113,242 shares in the company.
Cramer Rosenthal Mcglynn LLC Decreases Stock Position in BioLife Solutions, Inc. $BLFS
Cramer Rosenthal Mcglynn LLC significantly reduced its stake in BioLife Solutions, Inc. (NASDAQ:BLFS) by 86.3% in the third quarter, selling over 600,000 shares. Despite this reduction by one hedge fund, major institutional investors like Vanguard and Invesco increased their positions, showing continued institutional support for the company. Analysts maintain a "Moderate Buy" rating with an average target price of $32, though recent insider sales and a negative P/E ratio may impact near-term sentiment.
Karen Foster Sells 96,923 Shares of BioLife Solutions (NASDAQ:BLFS) Stock
Karen Foster, an insider at BioLife Solutions (NASDAQ:BLFS), sold 96,923 shares of the company's stock on March 5th at an average price of $20.15, totaling $1.95 million. This transaction reduced her stake by 46.01% to 113,742 shares. The stock is currently trading around $19.90, below its 50- and 200-day moving averages, but analysts maintain a "Moderate Buy" rating with an average target price of $32.00.
Insider Sell: Karen Foster Sells 97,423 Shares of BioLife Soluti
Karen Foster, Chief Quality and Operations Officer at a BioLife Solutions Inc (BLFS) subsidiary, sold 97,423 shares of the company on March 9, 2026. After this transaction, Foster now holds 113,242 shares. The stock was trading at $20.15 per share, and with a GF Value of $24.91, it is considered modestly undervalued.
BioLife Solutions (BLFS) executive sells 418 shares to cover tax withholding
Karen A. Foster, Chief Quality and Operations at BioLife Solutions (BLFS), sold 418 shares of common stock at $20.74 per share to cover tax withholding obligations. This transaction was conducted under a Rule 10b5-1(c) trading plan established to manage tax liabilities from restricted stock vesting. Following the sale, Foster directly owns 210,665 shares of the company.
BioLife Solutions, Inc. $BLFS Shares Purchased by Vanguard Group Inc.
Vanguard Group Inc. increased its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS) by 2.4% in the third quarter, bringing their total ownership to 6.19% of the company, valued at $75.7 million. Despite recent insider selling and mixed analyst ratings, the company is focusing on core biopreservation media and vials, with analysts setting a consensus "Moderate Buy" target price of $32. The stock has a market cap of $959.24 million and institutional investors now own 93.24% of the company.
BioLife Solutions Hits Day High with Strong 7.65% Intraday Surge
BioLife Solutions, Inc. saw its stock price surge by 7.65% on February 27, 2026, reaching an intraday high of USD 25.25. The company reported a 10.41% increase in net sales and has achieved positive results for four consecutive quarters, alongside 100% institutional holdings. Despite these positive indicators, the stock has experienced a 38.31% decline over the past five years.
BioLife Solutions (NASDAQ:BLFS) EVP Aby Mathew Sells 529 Shares
BioLife Solutions (NASDAQ:BLFS) EVP Aby Mathew sold 529 shares of the company's stock on March 3rd, 2026, for a total of $10,971.46. This transaction decreased his ownership by 0.13%, leaving him with 392,937 shares valued at over $8 million. The stock subsequently traded down 2.7% to $20.12, and analysts currently assign a "Moderate Buy" rating with a consensus price target of $32.00.
A Look At BioLife Solutions (BLFS) Valuation After Earnings Beat And 2026 Growth Guidance
BioLife Solutions (BLFS) recently reported strong Q4 and full-year 2025 results with positive 2026 growth guidance, including double-digit revenue growth and anticipated full-year GAAP profitability. Despite operational progress, the stock has seen declines, leading to a narrative that pegs its fair value at $32.44, indicating it is undervalued compared to its last close of $20.17. However, its current P/S ratio is significantly higher than the industry average, suggesting mixed signals on its valuation.
[Form 4] BIOLIFE SOLUTIONS INC Insider Trading Activity
BioLife Solutions Inc.'s Chief Financial Officer, Troy Wichterman, reported an open-market sale of 588 shares of common stock at $20.74 per share on March 3, 2026. This transaction was conducted under a Rule 10b5-1(c) trading plan to cover tax withholding obligations related to restricted stock vesting. Following the sale, Wichterman still directly holds 220,649 shares of the company's common stock.
BLFS SEC Filings - Biolife Solutions Inc 10-K, 10-Q, 8-K Forms
This page provides access to BioLife Solutions Inc. (BLFS) SEC filings, including annual 10-K reports, quarterly 10-Q reports, 8-K material event filings, and insider trading forms. It offers detailed information on the company's activities as a developer and supplier of cell processing tools and bioproduction products for the cell and gene therapy markets. The platform uses AI-powered summaries to explain key points from these regulatory documents, helping investors understand BioLife's financial performance, corporate governance, and significant events.
BioLife Solutions (BLFS) -10%: Stock Drops on 'Sell the News' Reaction to Strong Guidance
BioLife Solutions (BLFS) experienced a 10% stock drop. This decrease is attributed to a "sell the news" reaction, despite the company providing strong guidance. The article suggests investors reacted negatively after the guidance was released, likely taking profits.
BioLife Solutions (BLFS) details 2025 surge and 2026 profit outlook
BioLife Solutions (BLFS) has announced a strong financial performance in 2025, with pro forma revenue reaching $96 million and a 29% organic growth rate after strategic divestitures. The company's adjusted EBITDA margin hit 26% and gross margin approximately 65%, driven by a focus on high-margin biopreservation media and cell processing tools for cell-based therapies. Looking ahead to 2026, BioLife Solutions forecasts 17–20% revenue growth, positive GAAP net income, and continued expansion of its adjusted EBITDA margin.
Does BioLife’s 2026 Profitability Guidance and Media Strength Change The Bull Case For BLFS?
BioLife Solutions (BLFS) recently reported strong Q4 and full-year 2025 results, alongside positive 2026 revenue and GAAP net income guidance. This outlook, driven by their biopreservation media and refocused consumables, reinforces the company's near-term investment narrative centered on profitability and recurring sales. While the guidance supports a positive outlook, risks such as high customer concentration in cell processing revenue remain, and fair value estimates vary significantly among analysts.
Does BioLife’s 2026 Profitability Guidance and Media Strength Change The Bull Case For BLFS?
BioLife Solutions (BLFS) recently reported its Q4 2025 and 2025 full-year results, showing significant sales growth and a reduced net loss, along with 2026 revenue guidance of US$112.5 million to US$115.0 million and expected GAAP net income. This positive outlook, particularly driven by its biopreservation media franchise, supports the company's investment narrative for near-term profitability. However, the article notes ongoing risks like high customer concentration in cell processing revenue and varying fair value estimates from the community.
Wall Street Analysts Believe BioLife Solutions (BLFS) Could Rally 35%: Here's is How to Trade
Shares of BioLife Solutions (BLFS) have recently gained 11%, closing at $24.2, and Wall Street analysts project a further 35% upside, with a mean price target of $32.67. This optimism is supported by a low standard deviation in analyst estimates and strong positive revisions in earnings estimates, leading to a Zacks Rank #1 (Strong Buy). However, the article cautions investors to treat price targets with skepticism, emphasizing that while they can be a starting point for research, strong agreement on earnings revisions is a more reliable indicator of potential upside.
BLFS Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Biolife Solutions Inc (BLFS) based on its SEC filings. It includes comprehensive data on the company's income statement, balance sheet, cash flow, and key financial ratios, covering annual fundamentals and quarterly data with growth rates. The report indicates a mixed financial health profile with strong liquidity and low leverage but thin profitability and mixed earnings quality.
BioLife Solutions (NASDAQ:BLFS) Shares Gap Up - What's Next?
BioLife Solutions (NASDAQ:BLFS) shares gapped up following a strong Q4 earnings beat and raised 2026 revenue guidance, exceeding analyst expectations. The company reported $24.8M in Q4 revenue, a 20% year-over-year increase, with GAAP net income of $2.1M and adjusted EBITDA of $6.9M. BioLife also noted an expanding mix of commercial customers, which is expected to reduce revenue volatility.
Can BioLife Solutions Capitalize On The Explosive Growth Of The Cell And Gene Therapy Market?
BioLife Solutions Inc. (BLFS) is positioned to benefit from the rapidly expanding cell and gene therapy market, with its products used in a significant percentage of clinical trials and commercial therapies. The company reported a strong financial performance in 2025, achieving non-GAAP net income of $6.3 million and a 29% revenue increase to $96.2 million from continuing operations. BioLife Solutions projects continued revenue growth of 17% to 20% for 2026, targeting $112.5 million to $115.0 million.
BioLife Solutions Inc reports results for the quarter ended September 30 - Earnings Summary
BioLife Solutions Inc. has reported its financial results for the quarter that ended on September 30. The earnings summary is provided by Refinitiv and is a one-minute read. The article is sourced from Reuters and focuses on the company's (BLFS) analyst earnings.
[Form 4] BIOLIFE SOLUTIONS INC Insider Trading Activity
BioLife Solutions Inc. director Timothy L. Moore reported the acquisition of 8,170 restricted shares of common stock through a Form 4 filing. The shares were granted under the BioLife Solutions 2023 Performance Incentive Plan at a price of $0.0000 per share and will fully vest on January 2, 2026. Following this transaction, Moore directly holds 44,943 shares of the company's common stock.
BioLife Solutions (BLFS) director awarded 8,170 restricted shares
Catherine Coste, a director at BioLife Solutions (BLFS), was granted 8,170 restricted shares of common stock at no cash price under the company's 2023 Performance Incentive Plan. These shares will fully vest on January 2, 2027, which is the first anniversary of the vesting date of January 2, 2026. Following this award, Coste's direct beneficial ownership in BioLife Solutions totals 13,871 common shares.
BioLife Solutions (NASDAQ:BLFS) Posts Quarterly Earnings Results, Beats Estimates By $0.24 EPS
BioLife Solutions (NASDAQ:BLFS) announced strong quarterly earnings, reporting $0.22 EPS, which significantly beat analyst estimates of ($0.02) by $0.24. The company's Q4 revenue reached $24.8 million, exceeding the consensus estimate of $24.01 million. BioLife Solutions closed FY2025 with $96.2 million in revenue and expects 2026 revenue of $112.5–115 million, with plans for its first full-year GAAP net income.
BioLife Solutions to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 26, 2026
BioLife Solutions (NASDAQ: BLFS) announced it will report its fourth quarter and full-year 2025 financial results on February 26, 2026. The company will host a conference call and live webcast at 4:30 PM ET to discuss the financial results and provide a business update. A replay of the webcast will be available for 90 days on their investor relations website.
BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market
BioLife Solutions, Inc. has entered into a multi-year supply agreement with Qkine Limited to distribute specific cytokine and growth factor products for the cell and gene therapy (CGT) market. This partnership grants BioLife exclusive global distribution rights for certain Qkine products and non-exclusive rights for others in the CGT sector. The collaboration aims to integrate Qkine’s products with BioLife’s CellSeal® Connect vial system and enhance BioLife's offerings in the rapidly growing cytokines market.
BioLife Solutions, Inc. (BLFS): Analyst Consensus Signals 45.95% Potential Upside
BioLife Solutions, Inc. (BLFS) is attracting significant investor attention within the healthcare sector, particularly in cell and gene therapy. Despite negative earnings, the company shows strong revenue growth and innovative product offerings, leading analysts to project a 45.95% potential upside with an average target price of $32.44. Technical indicators are mixed, but overwhelmingly positive analyst sentiment suggests confidence in its future performance.
BioLife Solutions to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 26, 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) announced it will release its 2025 fourth quarter and full year financial results on February 26, 2026. The company will host a conference call and live webcast at 4:30 PM ET that day to discuss the financial results and provide a business update. A webcast replay will be available for 90 days following the call.
BioLife Solutions to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 26, 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) announced it will release its fourth quarter and full year 2025 financial results on February 26, 2026. The company will host a conference call and live webcast at 4:30 PM ET on that day to provide an overview of the financial results and a general business update. BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy market.
BioLife Solutions to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 26, 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) announced it will release its 2025 fourth quarter and full year financial results on February 26, 2026. The company will host a conference call and live webcast at 4:30 PM ET (1:30 PM PT) on that day to discuss the results and provide a business update. Investors and interested parties can access the webcast via the company's investor relations website.
How BioLife’s Exclusive Qkine Cytokine Deal Could Rewire the BLFS Cell and Gene Therapy Story
BioLife Solutions recently announced an exclusive multi-year distribution agreement with Qkine Limited for cytokine and growth factor products used in cell and gene therapy manufacturing. This deal expands BioLife's reach into the growing cytokines market, estimated to double to US$1 billion by 2030, and aims to integrate Qkine's products into BioLife’s CellSeal® Connect vial system. The partnership is expected to strengthen BioLife’s investment narrative by adding a new revenue stream and deepening its role in CGT process optimization.
